Presentations

  Presentation Webcast
February 28, 2024 Investor update
November 22, 2023 Investor call with management team
Oktober 2, 2023 Presentation with CEO Jenny Sundqvist and CSO Charlotte Admyre at Redeye Autoimmune & Inflammatory Disease Event
August 31, 2023 Company presentation with CEO Jenny Sundqvist and CFO Johan Giléus at HC Andersen Capitals Life Science Seminar
August 2, 2023 Interview with CEO Jenny Sundqvist explaining the importance of the formulation patent for cobitolimod that was recently granted in Europe
June 19, 2023 Investor update with CEO Jenny Sundqvist and Deputy CEO and CFO Johan Giléus
June 1, 2023 In focus interview with CEO Jenny Sundqvist at Redeye Growth Day 2023
June 1, 2023 Investor call regarding license agreement in Japan
May 9, 2023 Business update with management team
April 20, 2023 Company presentation with CEO Jenny Sundqvist at Redeye Investor Forum Göteborg
March 28, 2023 Presentation with CEO Jenny Sundqvist and CDO Eva Arlander on the results of the PK study with cobitolimod
February 23, 2023 Interview with CEO Jenny Sundqvist regarding the year-end report for 2022
February 14, 2023 Presentation with CEO Jenny Sundqvist providing complementary information on the phase III program CONCLUDE with cobitolimod
February 13, 2023 Get to know interview with CEO Jenny Sundqvist
November 24, 2022 Redeye Life Science Day 2022 - In Focus Q&A
October 6, 2022 Presentation at Redeye Investor AW in Gothenburg
September 22, 2022 Deep dive presentation on the positive feedback from the Japanese regulatory authority (PMDA) on cobitolimod
June 9, 2022 Deep dive presentation on the commercialization strategy for cobitolimod
June 2, 2022 Redeye Growth Day 2022 In Focus Q&A
May 16, 2022 Q1 report interview with acting CEO Johan Giléus
March 31, 2022 Presentation at Redeye Investor Forum in Malmö
March 14, 2022 Capital Markets Day 2022
February 28, 2022 Deep dive into the mechanism of action of cobitolimod with CEO Peter Zerhouni and Senior Scientist Charlotte Admyre
February 25, 2022 Year-end report Interview with CEO Peter Zerhouni
January 27, 2022 CEO Peter Zerhouni and CMO Thomas Knittel make a deep dive into the design of the phase III study CONCLUDE
December 9, 2021 Presentation by CEO Peter Zerhouni at HC Andersen Capital's Virtual Growth Days Seminar
November 29, 2021 Interview with CEO Peter Zerhouni about the enrollment of the first patient in the phase III study CONCLUDE and the way forward
November 25, 2021 Presentation with CEO Peter Zerhouni at Erik Penser Banks Bolagsdag 2021
November 24, 2021 Presentation with CEO Peter Zerhouni and CMO Thomas Knittel on the highlights of the Q3 report and a deep dive into previous clinical studies with cobitolimod
November 11, 2021 Presentation at Redeye Life Science Day 2021
October 27, 2021 Company introduction at HC Andersen Capital's online event
October 7, 2021 Presentation at HC Andersen Capital Small & Mid cap seminar
September 2, 2021 Presentation at Pareto Securities’ Healthcare Conference 2021
August 27, 2021 Redeye interviews CEO Peter Zerhouni after the release of the Q2 report
June 15, 2021 Interview with CEO Peter Zerhouni about the phase III study CONCLUDE
June 2, 2021 Presentation at Redeye Growth Day
May 6, 2021 Presentation at Erik Penser Bank's theme day - commercialization of medicines
March 11, 2021 Presentation at Barclays Global Healthcare Conference
January 28, 2021 Redeye interviews CEO Peter Zerhouni about the latest events in the company and the plans for 2021
January 7, 2021 Interview with InDex CEO Peter Zerhouni about the eventful year 2020 and what awaits in 2021
December 8, 2020 InDex Pharmaceuticals R&D day
November 26, 2020 Presentation at Redeye Life Science Day
October 12, 2020 Presentation of CONDUCT study at UEGW and ACG
October 6, 2020 Interview with InDex about the publication of the phase IIb CONDUCT study results in the Lancet Gastroenterology and Hepatology
October 6, 2020 Redeye interviews CMO Dr Thomas Knittel about the publication of the CONDUCT study results in the Lancet Gastroenterology and Heptology
September 24, 2020 Interview with CEO Peter Zerhouni at Bolagsdagen Erik Penser Bank
September 24, 2020 Presentation at Bolagsdagen Erik Penser Bank
September 2, 2020 Interview with CEO Peter Zerhouni at Pareto Securities Healthcare Conference
June 2, 2020 Presentation at Redeye Growth Day 2020
May 4, 2020 Interview with CEO Peter Zerhouni in Nordic Life Science News
April 29, 2020 Interview with CEO Peter Zerhouni about the market research studies with physicians and patients
April 20, 2020 Teleconference – update on the phase III preparations
February 20, 2020 Interview with Professor Walter Reinisch on the results of the CONDUCT-study
February 20, 2020 CEO interview on the conclusions from the in-depth analysis of the CONDUCT study
December 12, 2019 Investor presentation at Redeye
November 19, 2019 Presentation at Avanza Börsdag
November 19, 2019 Presentation at Redeye Life Science Day
September 17, 2019 CEO Interview at Redeye
September 5, 2019 Presentation at Pareto Health Care Conference
September 5, 2019 CEO Interview at Pareto Health Care Conference
August 27, 2019 Presentation of CONDUCT top line results
August 27, 2019 CEO Inteview at Di TV
June 26, 2019 CEO Interview at Redeye
June 18, 2019 CEO Interview at Healthcare Direkt
June 10, 2019 Redeye Growth Day 2019
December 3, 2018 Redeye Investor After Work in Gothenburg
November 21, 2018 Redeye Life Science Seminar 2018
April 25, 2018 Capital Markets Day 2018
March 7, 2018 Stockholm Corporate Finance Life Science Seminar 2018
November 24, 2017 Redeye Life Science Seminar 2017
June 28, 2017 CEO Interview by Finwire
June 27, 2017 CEO Interview by Redeye
June 12, 2017 Småbolagsdagen 2017
April 27, 2017 Redeye Biotech Seminar 2017
March 22, 2017 Stockholm Corporate Finance Life Science Seminar 2017
November 15, 2016 Redeye Life Science Seminar 2016
October 11, 2016 Listing on First North Nasdaq Stockholm
September 14, 2016 Biostock Academy meets InDex Pharmaceuticals
September 12, 2016 Aktiedagen 2016
August 24, 2016 CEO Interview by Finwire
Deep dive presentation on the positive feedback from the Japanese regulatory authority on cobitolimod